B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling

Current Opinion in Immunology

Volumn 19, Issue 3, 2007, Pages 327-336

  Mackay, Fabienne ^a   Silveira, Pablo A ^a   Brink, Robert ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AUTOIMMUNITY; B LYMPHOCYTE; CELL MATURATION; CELL SURVIVAL; HUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL DIFFERENTIATION; HUMANS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 34247574625     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2007.04.008     Document Type: Review

References (113)

1. Mackay F., Sierro F., Grey S.T., and Gordon T.P. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 8 (2005) 243-265
2. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 17 (2005) 282-289
3. Ng L.G., Mackay C.R., and Mackay F. The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 42 (2005) 763-772
4. Tangye S.G., Bryant V.L., Cuss A.K., and Good K.L. BAFF, APRIL and human B cell disorders. Semin Immunol 18 (2006) 305-317
5. Haiat S., Billard C., Quiney C., Ajchenbaum-Cymbalista F., and Kolb J.P. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 118 (2006) 281-292
6. Szodoray P., and Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 62 (2005) 421-428
7. Kalled S.L. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204 (2005) 43-54
8. Kalled S.L., Ambrose C., and Hsu Y.M. The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun 8 (2005) 206-242
9. Miller J.P., Stadanlick J.E., and Cancro M.P. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 176 (2006) 6405-6410
10. Dillon S.R., Gross J.A., Ansell S.M., and Novak A.J. An APRIL to remember: novel TNF ligands as therapeuthic targets. Nat Rev Drug Discov 5 (2006) 235-246
11. Mackay F., and Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 18 (2006) 284-289. This is the first review compiling all the data about the role of the BAFF/APRIL system on T-cell biology. This review highlights future areas of investigation and the possibility of additional biological functions controlled by the BAFF/APRIL system.
12. Mackay F., Schneider P., Rennert P., and Browning J.L. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 21 (2003) 231-264
13. Bodmer J.L., Schneider P., and Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 27 (2002) 19-26
14. Lopez-Fraga M., Fernandez R., Albar J.P., and Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2 (2001) 945-951
15. Gavin A.L., AÏt-Azzouzene D., Ware C.F., and Nemazee D. ΔBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 278 (2003) 38220-38228
16. Gavin A.L., Duong B., Skog P., Ait-Azzouzene D., Greaves D.R., Scott M.L., and Nemazee D. ΔBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 175 (2005) 319-328
17. Roschke V., Sosnovtseva S., Ward C.D., Hong J.S., Smith R., Albert V., Stohl W., Baker K.P., Ulrich S., Nardelli B., et al. BLyS and APRIL form biologically active heteromers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 169 (2002) 4314-4321
18. Pradet-Balade B., Medema J.P., Lopez-Fraga M., Lozano J.C., Kolfschoten G.M., Picard A., Martinez-A C., Garcia-Sanz J.A., and Hahne M. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 21 (2002) 5711-5720
19. Hahne M., Kataoka T., Schroter M., Hofmann K., Irmler M., Bodmer J.L., Schneider P., Bornand T., Holler N., French L., et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor growth. J Exp Med 188 (1998) 1185-1190
20. Litinskiy M.B., Nardelli B., Hilbert B.M., Bing H., Schaffer A., Casali P., and Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3 (2002) 822-829
21. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., Sosnovtseva S., Carrell J.A., Feng P., Giri J.G., et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97 (2000) 198-204
22. Munoz-Fernandez R., Blanco F.J., Frecha C., Martin F., Kimatrai M., Abadia-Molina A.C., Garcia-Pacheco J.M., and Olivares E.G. Follicular dendritic cells are related to bone marrow stromal cell progenitors and to myofibroblasts. J Immunol 177 (2006) 280-289
23. Kato A., Truong-Tran A.Q., Scott A.L., Matsumoto K., and Schleimer R.P. Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-β-dependent mechanism. J Immunol 177 (2006) 7164-7172
24. Ittah M., Miceli-Richard C., Gottenberg J.-E., Lavie F., Lazure T., Ba N., Sellam J., Lepajolec C., and Mariette X. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 8 (2006) R51
25. Ohata J., Zvaifler N.J., Nishio M., Boyle D.L., Kalled S.L., Carson D.A., and Kipps T.J. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 174 (2005) 864-870
26. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., Kalled S.L., Hess D.M., Serafini B., Aloisi F., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201 (2005) 195-200. This is an interesting study that links BAFF expression with autoimmunity in the central nervous system - a pathology more traditionally linked to self-reactive T-cell activity.
27. Schaumann D.H., Tuischer J., Ebell W., Manz R.A., and Lauster R. VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF. Mol Immunol 44 (2007) 1617-1623
28. Abe M., Kido S., Hiasa M., Nakano A., Oda A., Amou H., and Matsumoto T. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 20 (2006) 1313-1315
29. Moon E.Y., Lee J.H., Oh S.Y., Ryu S.K., Kim H.M., Kwak H.S., and Yoon W.K. Reactive oxygen species augment B-cell-activating factor expression. Free Radic Biol Med 40 (2006) 2103-2111
30. Klein B., Tarte K., Jourdan M., Mathouk K., Moreaux J., Jourdan E., Legouffe E., De Vos J., and Rossi J.F. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78 (2003) 106-113
31. Avery D.T., Kalled S.L., Ellyard J.I., Ambrose C., Bixler S.A., Thien M., Brink R., Mackay F., Hodgkin P.D., and Tangye S.G. BAFF selectively enhances the survival of plasmablasts generated from human memory cells. J Clin Invest 112 (2003) 286-297
32. Laabi Y., Gras M.P., Brouet J.C., Berger R., Larsen C.J., and Tsapis A. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res 22 (1994) 1147-1154
33. Ng L.G., Sutherland A., Newton R., Qian F., Cachero T.G., Scott M.L., Thompson J.S., Wheway J., Chtanova T., Groom J., et al. BAFF-R is the principal BAFF receptor facilitating BAFF co-stimulation of B and T cells. J Immunol 173 (2004) 807-817
34. Chang S.K., Arendt B.K., Darce J.R., Wu X., and Jelinek D.F. A role for BLyS in the activation of innate immune cells. Blood 108 (2006) 2687-2694
35. Bossen C., and Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18 (2006) 263-275. This is an interesting review that reveals two novel features in the BAFF/APRIL system: heparan sulfate proteoglycans, which are novel receptors for APRIL, and a short form of APRIL, which is able to bind to BAFF-R.
36. Mackay F., and Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 14 (2003) 311-324
37. Gorelik L., Gilbride K., Dobles M., Kalled S.L., Zandman D., and Scott M.L. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 198 (2003) 937-945
38. Pelletier M., Thompson J.S., Qian F., Bixler S.A., Gong D., Cachero T.G., Gilbride K., Day E., Zafari M., Benjamin C., et al. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem 278 (2003) 33127-33133
39. Smith S.H., and Cancro M.P. B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J Immunol 170 (2003) 5820-5823
40. Varfolomeev E., Kischkel F., Martin F., Seshasayee D., Wang H., Lawrence D.A., Olsson C., Tom L., Erickson S., French D., et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 24 (2004) 997-1006
41. Walmsley M.J., Ooi S.K.T., Reynolds L.F., Smith S.H., Ruf S., Mathiot A., Vanes L., Williams D.A., Cancro M.P., and Tybulewicz V.L.J. Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science 302 (2003) 459-462
42. Castigli E., Scott S., Dedeoglu F., Bryce P., Jabara H., Bhan A.K., Mizoguchi E., and Geha R.S. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 101 (2004) 3903-3908
43. von Bulow G.U., Russell H., Copeland N.G., Gilbert D.J., Jenkins N.A., and Bram R.J. Molecular cloning and functional characterization of murine transmembrane activator and CAML interactor (TACI) with chromosomal localization in human and mouse. Mamm Genome 11 (2000) 628-632
44. von Bulow G.-U., van Deursen J.M., and Bram R.J. Regulation of the T-independent humoral response by TACI. Immunity 14 (2001) 573-582
45. Seshasayee D., Valdez P., Yan M., Dixit V.M., Tumas D., and Grewal I.S. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18 (2003) 279-288
46. Castigli E., Wilson S.A., Garibyan L., Rachid R., Bonilla F., Schneider L., and Geha R.S. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 37 (2005) 829-834. This article describes mutations in the TACI gene associated with immunodeficiency in humans. This article is very interesting as it suggests a different role for TACI in mice and humans.
47. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 18 (2006) 276-283
48. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., and Cyster J.G. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20 (2004) 441-453
49. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., and Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20 (2004) 785-798
50. Ait-Azzouzene D., Gavin A.L., Skog P., Duong B., and Nemazee D. Effect of cell:cell competition and BAFF expression on peripheral B cell tolerance and B-1 cell survival in transgenic mice expressing a low level of Igκ-reactive macroself antigen. Eur J Immunol 36 (2006) 985-996
51. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., Tschopp J., and Browning J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 (1999) 1697-1710
52. Khare S.D., Sarosi I., Xia X.-Z., McCabe S., Miner K., Solovyev I., Hawkins N., Kelley M., Chang D., Chang D., et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 97 (2000) 3370-3375
53. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., Xu W., Parrish-Novak J., Forster D., Lofton-Day C., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
54. Zhang M., Ko K.H., Lam Q.L., Lo C.K., Srivastava G., Zheng B., Lau Y.L., and Lu L. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol 17 (2005) 1081-1092
55. Zheng Y., Gallucci S., Gaughan J.P., Gross J.A., and Monestier M. A role for B cell-activating factor of the TNF family in chemically induced autoimmunity. J Immunol 175 (2005) 6163-6168
56. Jiang Y., Ohtsuji M., Abe M., Li N., Xiu Y., Wen S., Shirai T., and Hirose S. Polymorphism and chromosomal mapping of the mouse gene for B-cell activationg factor belonging to the tumor necrosis factor family (Baff) and association with autoimmune phenotype. Immunogenetics 53 (2001) 810-813
57. Kawasaki A., Tsuchiya N., Fukazawa T., Hashimoto H., and Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 3 (2002) 424-429
58. Gottenberg J.E., Sellam J., Ittah M., Lavie F., Proust A., Zouali H., Sordet C., Sibilia J., Kimberly R.P., Mariette X., et al. No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjogren's syndrome. Arthritis Res Ther 8 (2006) R30
59. Koyama T., Tsukamoto H., Masumoto K., Himeji D., Hayashi K., Harada M., and Horiuchi T. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology (Oxford) 42 (2003) 980-985
60. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., Grewal I.S., Cochran A.G., Gordon N.C., Yin J., et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 10 (2002) 515-524
61. Ramanujam M., Wang X., Huang W., Schiffer L., Grimaldi C., Akkerman A., Diamond B., Madaio M.P., and Davidson A. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 173 (2004) 3524-3534
62. Ramanujam M., Wang X., Huang W., Liu Z., Schiffer L., Tao H., Frank D., Rice J., Diamond B., Yu K.O., et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116 (2006) 724-734. This study examines the therapeutic effects of blocking BAFF and APRIL compared with blocking BAFF alone in SLE-prone mice. Despite showing a few minor differences, both strategies depleted mature peripheral B-cell subsets and were equally protective, suggesting that protection is mainly mediated by BAFF neutralization.
63. Chan O.T.M., Hannum L.G., Haberman A.M., Madaio M.P., and Schlomchik M.J. A novel mouse with B cells lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189 (1999) 1639-1647
64. Shlomchik M.J., Craft J.E., and Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1 (2001) 147-153
65. 1 isotype, which are less capable of causing glomerular pathology.
66. Wang H., Marsters S.A., Baker T., Chan B., Lee W.P., Fu L., Tumas D., Yan M., Dixit V.M., Ashkenazi A., et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2 (2001) 632-637
67. Huntington N.D., Tomioka R., Clavarino C., Chow A.M., Linares D., Mana P., Rossjohn J., Cachero T.G., Qian F., Kalled S.L., et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 18 (2006) 1473-1485
68. Gilbert J.A., Kalled S.L., Moorhead J., Hess D.M., Rennert P., Li Z., Khan M.Z., and Banga J.P. Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology 147 (2006) 4561-4568
69. Stohl W. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun 8 (2005) 289-304
70. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., and Mariette X. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis 66 (2007) 700-702
71. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., Lappin P.B., Riccobene T., Abramian D., Sekut L., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48 (2003) 3253-3265
72. Furie R., Stohl W., Ginzler E., Becker M., Mishra N., Chatlam W., Merrill J.T., Weinstein A., McCune W.J., Zhong J., et al. Safety, pharmacokinetic and pharmacodynamic results of a Phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 48 (2003) S377
73. Halpern W.G., Lappin P., Zanardi T., Cai W., Corcoran M., Zhong J., and Baker K.P. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 91 (2006) 586-599
74. Vugmeyster Y., Seshasayee D., Chang W., Storn A., Howell K., Sa S., Nelson T., Martin F., Grewal I., Gilkerson E., et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol 168 (2006) 476-489
75. Cohen S.B. Updates from B cell trials: efficacy. J Rheumatol Suppl 77 (2006) 12-17
76. Batten M., Fletcher C., Ng L., Groom J., Wheway J., Laâbi Y., Xin X., Schneider P., Tschopp J., Mackay C.R., et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphomas. J Immunol 172 (2004) 812-822
77. Planelles L., Carvalho-Pinto C.E., Hardenberg G., Smaniotto S., Savino W., Gomez-Caro R., Alvarez-Mon M., de Jong J., Eldering E., Martinez A.C., et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6 (2004) 399-408
78. Chiu A., Xu W., He B., Dillon S.R., Gross J.A., Sievers E., Qiao X., Santini P., Hyjek E., Lee J.W., et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 109 (2006) 729-739
79. Elsawa S.F., Novak A.J., Grote D.M., Ziesmer S.C., Witzig T.E., Kyle R.A., Dillon S.R., Harder B., Gross J.A., and Ansell S.M. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 107 (2006) 2882-2888
80. Briones J., Timmerman J.M., Hilbert D.M., and Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 30 (2002) 135-141
81. He B., Chadburn A., Jou E., Schattner E.J., Knowles D.M., and Cerutti A. Lymphoma B cells evade apoptosis through the TNF family BAFF/BLyS and APRIL. J Immunol 172 (2004) 3268-3279
82. Kern C., Cornuel J.F., Billard C., Tang R., Rouillard D., Stenou V., Defrance T., Ajchenbaum-Cymbalista F., Simonin P.Y., Feldblum S., et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103 (2004) 679-688
83. Novak A.J., Bram R.J., Kay N.E., and Jelinek D.F. Aberrant expression of B-lymphocyte stimulator by chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100 (2002) 2973-2979
84. Novak A.J., Grote D.M., Stenson M., Ziesmer S.C., Witzig T.E., Habermann T.M., Harder B., Ristow K.M., Bram R.J., Jelinek D.F., et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104 (2004) 2247-2253
85. Novak A.J., Darce J.R., Arendt B.K., Harder B., Henderson K., Kindsvogel W., Gross J.A., Greipp P.R., and Jelinek D.F. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103 (2004) 689-694
86. Moreaux J., Legouffe E., Jourdan E., Quittet P., Reme T., Lugagne C., Moine P., Rossi J.F., Klein B., and Tarte K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103 (2004) 3148-3157
87. Nishio M., Endo T., Tsukada N., Ohata J., Kitada S., Reed J.C., Zvaifler N.J., and Kipps T.J. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α. Blood 106 (2005) 1012-1020
88. Claudio E., Brown K., Park S., Wang H., and Siebenlist U. BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat Immunol 3 (2002) 958-965
89. Liao G., Zhang M., Harhaj E.W., and Sun S.C. Regulation of the NF-κB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 279 (2004) 26243-26250
90. He J.Q., Zarnegar B., Oganesyan G., Saha S.K., Yamazaki S., Doyle S.E., Dempsey P.W., and Cheng G. Rescue of TRAF3-null mice by p100 NF-κB deficiency. J Exp Med 203 (2006) 2413-2418. Demonstration, through the production of a compound gene knockout mouse, of the regulatory link between TRAF3 and NF-κB2.
91. Grech A.P., Amesbury M., Chan T., Gardam S., Basten A., and Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity 21 (2004) 629-642
92. Enzler T., Bonizzi G., Silverman G.J., Otero D.C., Widhopf G.F., Anzelon-Mills A., Rickert R.C., and Karin M. Alternative and classical NF-κB signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25 (2006) 403-415
93. Sasaki Y., Derudder E., Hobeika E., Pelanda R., Reth M., Rajewsky K., and Schmidt-Supprian M. Canonical NF-κB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 24 (2006) 729-739. In this article, carefully designed genetically modified mouse models are used to unravel a complex in vivo problem, in this case the role of the classical NF-κB pathway in mature B-cell survival. This demonstrates that constitutive activation of the canonical NF-κB pathway can facilitate B-cell survival in the absence of BAFF-R expression.
94. Ramakrishnan P., Wang W., and Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-κB activation pathways by NF-κB-inducing kinase. Immunity 21 (2004) 477-489
95. Miosge L.A., Blasioli J., Blery M., and Goodnow C.C. Analysis of an ethylnitrosourea-generated mouse mutation defines a cell intrinsic role of nuclear factor κB2 in regulating circulating B cell numbers. J Exp Med 196 (2002) 1113-1119
96. Woodland R.T., Schmidt M.R., and Thompson C.B. BLyS and B cell homeostasis. Semin Immunol 18 (2006) 318-326
97. Mecklenbrauker I., Kalled S.L., Leitges M., Mackay F., and Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCδ-mediated nuclear signaling. Nature 431 (2004) 456-461
98. Plas D.R., Rathmell J.C., and Thompson C.B. Homeostatic control of lymphocyte survival: potential origins and implications. Nat Immunol 3 (2002) 515-521
99. Patke A., Mecklenbrauker I., Erdjument-Bromage H., Tempst P., and Tarakhovsky A. BAFF controls B cell metabolic fitness through a PKCβ- and Akt-dependent mechanism. J Exp Med 203 (2006) 2551-2562. This is an absorbing, thorough analysis of the signaling cascades and gene expression profile activated upon the addition of BAFF to mature B cells. It reveals a level of complexity in the response to BAFF that is much greater than was previously appreciated.
100. Qian Y., Qin J., Cui G., Naramura M., Snow E.C., Ware C.F., Fairchild R.L., Omori S.A., Rickert R.C., Scott M., et al. Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. Immunity 21 (2004) 575-587
101. Craxton A., Draves K.E., Gruppi A., and Clark E.A. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 202 (2005) 1363-1374
102. Endo T., Nishio M., Enzler T., Cottam H.B., Fukuda T., James D.F., Karin M., and Kipps T.J. BAFF And APRIL support chronic lymphocytic leukemia B cell survival through activation of the canonical NF-κB pathway. Blood 109 (2006) 703-710
103. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., and Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050 (2005) 34-39
104. Schaller M., Stohl W., Tan S.M., Benoit V.M., Hilbert D.M., and Ditzel H.J. Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis. Ann Rheum Dis 64 (2005) 743-749
105. Thangarajh M., Masterman T., Rot U., Duvefelt K., Brynedal B., Karrenbauer V.D., and Hillert J. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 167 (2005) 210-214
106. Krumbholz M., Specks U., Wick M., Kalled S.L., Jenne D., and Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 25 (2005) 298-302
107. Asashima N., Fujimoto M., Watanabe R., Nakashima H., Yazawa N., Okochi H., and Tamaki K. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 155 (2006) 330-336
108. Thangarajh M., Masterman T., Helgeland L., Rot U., Jonsson M.V., Eide G.E., Pirskanen R., Hillert J., and Jonsson R. The thymus is a source of B-cell-survival factors - APRIL and BAFF - in myasthenia gravis. J Neuroimmunol 178 (2006) 161-166
109. Kang J.S., Yoon Y.D., Ahn J.H., Kim S.C., Kim K.H., Kim H.M., and Moon E.Y. B cell-activating factor is a novel diagnosis parameter for asthma. Int Arch Allergy Immunol 141 (2006) 181-188
110. He B., Raab-Traub N., Casali P., and Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 171 (2003) 5215-5224
111. + T cells: lessons from HIV-infected patients. Clin Immunol 104 (2002) 115-122
112. Toubi E., Gordon S., Kessel A., Rosner I., Rozenbaum M., Shoenfeld Y., and Zuckerman E. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 27 (2006) 134-139
113. Moreaux J., Cremer F.W., Reme T., Raab M., Mahtouk K., Kaukel P., Pantesco V., De Vos J., Jourdan E., Jauch A., et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106 (2005) 1021-1030